share_log

On November 22, Kronos Bio Board Approved Approximately 83% Reduction In Its Workforce; Norbert Bischofberger Resigns As President And CEO, Effective December 3, 2024 - Filing

Benzinga ·  Nov 27, 2024 19:08

The workforce reduction is expected to be substantially completed on December 31, 2024.

In connection with the reduction in workforce, the Company expects to incur a charge of approximately $3.7 million relating to the cash-based expense of the employee severance, benefits, and related costs.

The Company anticipates payments associated with the workforce reduction will be substantially complete by the end of the first quarter of 2025.

On November 22, 2024, Deborah Knobelman, the Company's Chief Financial Officer and Chief Operating Officer, was appointed to serve as President and Interim Chief Executive Officer, effective December 3, 2024. Knobelman will also continue to serve as the Company's Chief Financial Officer and Chief Operating Officer.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment